Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
10.88
+0.24 (2.26%)
May 12, 2026, 3:04 PM CST
Xiangxue Pharmaceutical Revenue
Xiangxue Pharmaceutical had revenue of 354.16M CNY in the quarter ending March 31, 2026, a decrease of -15.88%. This brings the company's revenue in the last twelve months to 1.53B, down -10.65% year-over-year. In the year 2025, Xiangxue Pharmaceutical had annual revenue of 1.60B, down -14.16%.
Revenue (ttm)
1.53B
Revenue Growth
-10.65%
P/S Ratio
4.71
Revenue / Employee
552.03K
Employees
2,769
Market Cap
7.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.60B | -263.25M | -14.16% |
| Dec 31, 2024 | 1.86B | -440.63M | -19.16% |
| Dec 31, 2023 | 2.30B | 112.22M | 5.13% |
| Jan 1, 2023 | 2.19B | -783.51M | -26.38% |
| Jan 1, 2022 | 2.97B | -101.51M | -3.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 3.61B |
| Anhui Huaheng Biotechnology | 2.95B |
| Novogene | 2.26B |
| Chengdu Kanghua Biological Products | 1.20B |
| Wuhan Keqian Biology Co.,Ltd | 932.09M |
| Acrobiosystems | 887.21M |
| Jiangsu Aidea Pharmaceutical Group | 699.33M |
| Shanghai OPM Biosciences | 453.39M |